Mon.Apr 29, 2024

article thumbnail

Revised Schedule M to streamline inspections & boost pharmaceutical standards: CDSCO official

AuroBlog - Aurous Healthcare Clinical Trials blog

The implementation of Revised Schedule M is set to revolutionize the pharma industry landscape by not only enhancing quality standards but also by streamlining regulatory processes, notably by minimizing duplicative inspections by various regulatory bodies of different countries, according to a senior Central Drugs Standard Control Organisation (CDSCO) official.

Drugs 166
article thumbnail

Sustainability in pharmaceutical manufacturing: a CDMO’s contribution

Bio Pharma Dive

Consideration of sustainability early in process development, throughout the entire development cycle, and across the entire supply chain must also become common practice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer receives FDA approval for haemophilia B gene therapy

Pharmaceutical Technology

Pfizer has received approval from the US Food and Drug Administration (FDA) for its one-time gene therapy BEQVEZ for haemophilia B.

article thumbnail

AstraZeneca, Daiichi look to broaden Enhertu use again with new study data

Bio Pharma Dive

The drug benefited people whose tumors have “ultralow” levels of HER2 protein, a result that could extend its reach in HER2-positive breast cancer.

Protein 260
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Cell and gene therapy companies trip at scalability hurdle

Pharmaceutical Technology

Experts hold scalability challenges and high costs accountable for market failures within the cell and gene therapy landscape.

article thumbnail

Breakthrough: Rare Gene Mutation Offers Clues to Preventing Type 1 Diabetes

AuroBlog - Aurous Healthcare Clinical Trials blog

A unique genetic mutation in two siblings – that has never been seen in anyone else – has been discovered by UK researchers at the University of Exeter, pointing the way towards new treatment options for type 1 diabetes.

Gene 190

More Trending

article thumbnail

Clinical trial companies see immense relevance on US FDA Electronic Submission Safety Reports

AuroBlog - Aurous Healthcare Clinical Trials blog

Clinical trial companies see immense relevance on US FDA Electronic Submission Safety Reports. The guidance provides instructions about how the individual case safety reports (ICSRs) from investigational new drug (IND) need to be supported with Adverse Event Reporting System (AERS).

article thumbnail

AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval

Pharmaceutical Technology

AstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically for the eosinophilic phenotype, in children aged 6-11 years in more than 80 countries, including the US, EU, and Japan.

147
147
article thumbnail

Prime gets FDA green light to begin first trial test of ‘prime editing’

Bio Pharma Dive

The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology.

article thumbnail

BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding

Pharmaceutical Technology

US regulators have added more Chinese biotech companies to the list of firms posing national security risks to the US.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Systems thinking: A new paradigm for clinical trial design and operations

Bio Pharma Dive

Applying a systems thinking framework to clinical trial design prompts purposeful and productive collaboration among stakeholders.

article thumbnail

PharmaLink partners with Recall Results on safety of drugs

Pharmaceutical Technology

PharmaLink has partnered with Recall Results for accurate and responsive drug recalls, withdrawals and market actions in the pharma industry.

Drugs 130
article thumbnail

FDA finalizes lab developed test rule over industry opposition

Bio Pharma Dive

Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.

article thumbnail

Duchenne Muscular Dystrophy: the global clinical trials landscape 2024

Pharmaceutical Technology

Clinical trials across the globe are investigating new treatments for Duchenne Muscular Dystrophy, improving muscular and skeletal health.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Deciphera sells for $2.4B, adding to upswing in biopharma M&A

Bio Pharma Dive

For Japan-based Ono Pharmaceutical, buying Deciphera offers a way to build out in cancer research as well as get a stronger foothold in the U.S. and European markets.

Marketing 114
article thumbnail

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Pharmaceutical Technology

Ono will gain access to Deciphera’s kinase inhibitor pipeline, which includes the CSF-1 inhibitor vimseltinib and ULK inhibitor DCC-3116.

130
130
article thumbnail

12 Questions with Dr Jay Shah

pharmaphorum

Get to know Dr Jay Shah, a prominent figure in the field of cardiovascular medicine, as he answers 12 intriguing questions about his role as Chief Medical Officer at Aktiia and his insights into the field.

Medicine 124
article thumbnail

Pierre Fabre’s vibegron gains CHMP positive opinion for OAB

Pharmaceutical Technology

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended vibegron for OAB in adults.

Medicine 130
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Merck, Huma alliance bears fruit with UK bladder cancer app

pharmaphorum

A partnership between Huma Therapeutics and Merck KGaA to develop digital support tools for cancer patients has borne fruit with the launch of a bladder cancer app in the UK

article thumbnail

Sino Biological concludes SignalChem acquisition for $48m

Pharmaceutical Technology

Sino Biological has concluded the acquisition of SignalChem Biotech (SCB) for $48m, expanding its portfolio and global presence.

130
130
article thumbnail

Japan's Ono pays $2.4B for Qinlock-maker Deciphera as biotech readies another approval run

Fierce Pharma

The price tag includes both the approved cancer drug Qinlock and another Deciphera candidate heading to the FDA’s desk in the coming months.

Drugs 130
article thumbnail

Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data

Pharmaceutical Technology

The expanded approval of Biktarvy was based on the Phase I trial data showing efficacy in pregnant HIV-positive individuals.

Trials 130
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group

BioSpace

Enlaza Therapeutics on Tuesday announced financing led by the Life Sciences Group of J.P. Morgan Asset Management’s Private Capital division, which the California-based company will use to build its pipeline of covalent biologics.

article thumbnail

Biodexa gains license for polyposis asset as stock more than doubles

Pharmaceutical Technology

Biodexa’s worldwide rights of eRapa come with a $17m grant from CPRIT to support the asset into Phase III clinical trials.

Licensing 130
article thumbnail

X4 Pharma gets first FDA okay for WHIM syndrome drug

pharmaphorum

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi (mavorixafor) can be used in patients aged 12 and over with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a congenital immunodeficiency characterised by low neutrophil counts that affects fewer than 1,000 people in the US.

Drugs 111
article thumbnail

“Profound concern” over WHO’s pandemic agreement, says AIDS charity

Pharmaceutical Technology

The AHF Global Public Health Institute has voiced concerns over WHO's proposed pandemic agreement.

130
130
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Ono swoops on Deciphera in $2.4 billion takeover

pharmaphorum

Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (GIST) therapy Qinlock. Ono is offering $26.50 per share in cash for the Waltham, Massachusetts-based company, saying the deal will enable it to “build a robust presence in oncology,” one of the group’s key priority areas.

111
111
article thumbnail

AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win

BioSpace

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.

Antibody 114
article thumbnail

J&J gets CHMP nod for Rybrevant in first-line lung cancer

pharmaphorum

CHMP backs EU approval of J&J's Rybrevant as a first-line therapy for NSCLC with EGFR exon 30 insertion mutations, filling a void left after Takeda's Exkivity was pulled from sale

Sales 110
article thumbnail

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership

BioSpace

Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.

115
115
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.